Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 20

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 10 that AKBA strengthened the intellectual property protection for its flagship therapy, Vafseo (vadadustat), after receiving a new patent listing in the FDA's Orange Book and notification of eligibility for a five-year extension of a composition of matter patent. The additions enhance the company's existing patent portfolio, which now includes 14 Orange Book-listed patents covering Vafseo with protection extending through 2036. These developments further support the company's efforts to protect the long-term value and commercial potential of the therapy.

Earlier on May 7, Akebia Therapeutics, Inc. (NASDAQ:AKBA) reported its first-quarter 2026 financial results, highlighting continued progress for Vafseo and its kidney disease pipeline. Vafseo net product revenue reached $15.8 million during the quarter, while the number of patients using the therapy increased approximately 60% compared with the end of the prior quarter. The company also reported around 1,025 prescribers, rep

Fuente original: Yahoo Finance (https://finance.yahoo.com/healthcare/articles/akebia-therapeutics-inc-akba-strengthens-131032418.html)